Abstract
Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have